// App-Quantinova.ai

ABS184 : RESULTS FROM A 52‐WEEK, PROSPECTIVE, NONINTERVENTIONAL STUDY OF INDIVIDUALS WITH SEVERE HAEMOPHILIA A RECEIVING PROPHYLAXIS: RATES OF BLEEDING, FVIII USE, AND QUALITY OF LIFE

Researchers

Presenter

  • G. Kenet

Principal Investigators

  • Y.-C. Chen

  • G. Lowe

  • C. Percy

  • H. Tran

  • A. von Drygalski

  • M. Trossart

  • M. Reding

  • J. Oldenburg

  • M. Mingot Castellano

  • Y. S. Park

  • F. Peyvandi

  • J. Quinn

  • N. Mitchell

  • M. Huang

  • B. Kim

Medical Centers

  • The National Hemophilia Center and Thrombosis Unit, and Amalia Biron Research Institute of Thrombosis and Hemostasis, Sheba Medical Center, Tel Hashomer, Tel Aviv University, Tel Aviv, Israel

  • Hemophilia Care and Research Center, Tri‐Service General Hospital, Taipei, Taiwan

  • West Midlands Comprehensive Care Haemophilia Centre, Queen Elizabeth Hospital, Birmingham, United Kingdom

  • Haemostasis & Thrombosis Unit, Haemophilia Treatment Centre, The Alfred Hospital, Melbourne, Australia

  • Department of Molecular Medicine, Scripps Research Institute, La Jolla, United States

  • Centre régional de traitement de l'hémophilie, Chu de Nantes, Nantes, France

  • Center for Bleeding and Clotting Disorders, University of Minnesota, Minneapolis, Minnesota, United States

  • Institute of Experimental Hematology and Transfusion Medicine, University Hospital Bonn, Bonn, Germany

  • Regional University Hospital Carlos Haya, Malaga, Spain

  • Kyung Hee University Hospital at Gangdong, Seoul, Korea, Republic of

  • University of Milan, Milan, Italy

  • BioMarin Pharmaceutical Inc., Novato, United States

Locations

  • Israel

  • China

  • United Kingdom

  • Australia

  • United States

  • France

  • Germany

  • Spain

  • Republic of South Korea

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Hemophilia

Biomarkers

  • N/A

Drug/Treatment

  • FVIII

Outcome

  • N/A


Study Design

  • Non Interventional

  • Multinational

  • Prospective

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A